Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models

Cancer Biology and Therapy

Volumn 12, Issue 8, 2011, Pages 680-690

  Mutrie, Jennifer C ^a   Chambers, Ann F ^a   Tuck, Alan B ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Breast cancer; Hsp90; Osteopontin; Predictive biomarker; Src kinase

Indexed keywords

HEAT SHOCK PROTEIN 90 INHIBITOR; OSTEOPONTIN; PROTEIN TYROSINE KINASE INHIBITOR; SHORT HAIRPIN RNA;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL MIGRATION; CLONOGENIC ASSAY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BENZODIOXOLES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE KNOCKDOWN TECHNIQUES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; OSTEOPONTIN; QUINAZOLINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TRANSFECTION;

EID: 80054120984     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.8.16440     Document Type: Article

References (54)

1. Sawyers CL. The cancer biomarker problem. Nature 2008; 452:548-52; PMID:18385728; DOI:10.1038/ nature06913.
2. Araujo J, Logothetis C. Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev 2010; 36:492-500.
3. Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, et al. Phase I safety, pharmacokinetics and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res 2010; 16:4876-83; PMID:20805299; DOI:10.1158/1078-0432.CCR-10-0748.
4. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010; 16:3526-32; PMID:20634194; DOI:10.1158/1078-0432.CCR-09-1834.
5. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6:587-95; PMID:19787002; DOI:10.1038/nrclinonc.2009. 129.
6. Elsberger B, Fullerton R, Zino S, Jordan F, Mitchell TJ, Brunton VG, et al. Breast cancer patients' clinical outcome measures are associated with src kinase family member expression. Br J Cancer 2010; 103:899-909.
7. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis. Cancer 2002; 94:344-51; PMID:11900220; DOI:10.1002/cncr. 10221.
8. Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, et al. Pp60c-src activation in lung adenocarcinoma. Eur J Cancer 2003; 39:1447-55; PMID:12826049; DOI:10.1016/S0959-8049(03)00276-4.
9. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003; 88:73-9; PMID:12504632; DOI:10.1006/gyno.2002.6851.
10. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is upregulated in hormone-refractory prostate cancer. Clin Cancer Res 2009; 15:3540-9; PMID:19447874; DOI:10.1158/1078-0432.CCR-08- 1857.
11. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 2004; 279:11051-64; PMID:14704150; DOI:10.1074/jbc.M310256200.
12. Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC. Heat shock protein 90: Inhibitors in clinical trials. J Med Chem 2010; 53:3-17; PMID:20055425; DOI:10.1021/jm9004708.
13. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010; 10:537-49; PMID:20651736; DOI:10.1038/nrc2887.
14. Li Y, Zhang T, Schwartz SJ, Sun D. New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential. Drug Resist Updat 2009; 12:17-27; PMID:19179103; DOI:10.1016/j.drup. 2008.12.002.
15. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008; 13:38-43; PMID:18190862; DOI:10.1016/j. drudis.2007.10.007.
16. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006; 13:125- 35; PMID:17259553; DOI:10.1677/erc.1.01324.
17. Chiosis G, Neckers L. Tumor selectivity of Hsp90 inhibitors: The explanation remains elusive. ACS Chem Biol 2006; 1:279-84; PMID:17163756; DOI:10.1021/cb600224w.
18. Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007; 67:2932-7; PMID:17409397; DOI:10.1158/0008-5472.CAN-06-4511.
19. Annamalai B, Liu X, Gopal U, Isaacs JS. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: Implications for cancer cell migration and metastasis. Mol Cancer Res 2009; 7:1021-32; PMID:19567782; DOI:10.1158/1541-7786.MCR- 08-0582.
20. Chen JS, Hsu YM, Chen CC, Chen LL, Lee CC, Huang TS. Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NFkappaB-mediated integrin alphaV expression. J Biol Chem 2010; 285:25458-66; PMID:20558745; DOI:10.1074/jbc.M110.139345.
21. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: Role in cell signaling and cancer progression. Trends Cell Biol 2006; 16:79-87; PMID:16406521; DOI:10.1016/j.tcb.2005.12.005.
22. Weber GF. The metastasis gene osteopontin: A candidate target for cancer therapy. Biochim Biophys Acta 2001; 1552:61-85; PMID:11825687.
23. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004; 90:1877-81; PMID:15138464; DOI:10.1038/sj.bjc.6601839.
24. Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management. J Cell Biochem 2007; 102:859-68; PMID:17721886; DOI:10.1002/jcb.21520.
25. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumor microenvironment. J Cell Mol Med 2010; 14:2037-44.
26. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145:610-23; PMID:8080043.
27. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10:184-90; PMID:14734468; DOI:10.1158/1078-0432.CCR-1405-2.
28. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998; 79:502-8; PMID:9761120; DOI:10.1002/ (SICI)1097-0215(19981023)79:5〈502::AIDIJC10〉3.0.CO;2-3.
29. Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006; 118:2255-61; PMID:16331611; DOI:10.1002/ ijc.21619.
30. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: Associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002; 95:506-12; PMID:12209742; DOI:10.1002/cncr.10709.
31. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94:513-21; PMID:11929952.
32. Imano M, Satou T, Itoh T, Sakai K, Ishimaru E, Yasuda A, et al. Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg 2009; 13:1577-82; PMID:19582521; DOI:10.1007/s11605- 009-0955-y.
33. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003; 9:416-23; PMID:12640447; DOI:10.1038/nm843.
34. Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, et al. Differential osteopontin expression in lung cancer. Cancer Lett 2001; 171:215-22; PMID:11520606; DOI:10.1016/S0304- 3835(01)00607-3.
35. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer 1996; 15:311-23; PMID:8959677; DOI:10.1016/0169-5002(95)00595-1.
36. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006; 12:3337-43; PMID:16740755; DOI:10.1158/1078-0432. CCR-05-2354.
37. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002; 62:3417-27; PMID:12067984.
38. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008; 122:889- 97; PMID:17960616; DOI:10.1002/ijc.23204.
39. Patani N, Jouhra F, Jiang W, Mokbel K. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res 2008; 28:4105- 10; PMID:19192668.
40. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 1997; 121:578-84; PMID:9199622.
41. Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): Multifunctional proteins in cancer. Nat Rev Cancer 2008; 8:212-26; PMID:18292776; DOI:10.1038/nrc2345.
42. Tuck AB, Hota C, Wilson SM, Chambers AF. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 2003; 22:1198-205; PMID:12606946; DOI:10.1038/ sj.onc.1206209.
43. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (met). J Cell Biochem 2000; 78:465-75; PMID:10861844; DOI:10.1002/1097-4644(20000901)78: 3〈465::AIDJCB11〉 3.0.CO;2-C.
44. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000; 11:279-303; PMID:11021631; DOI:10.1177/10454411000110030101.
45. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, et al. Role of the integrinbinding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 2006; 169:233-46; PMID:16816376; DOI:10.2353/ajpath. 2006.051152.
46. Schulze EB, Hedley BD, Goodale D, Postenka CO, Al-Katib W, Tuck AB, et al. The thrombin inhibitor argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontinindependent mechanisms. Breast Cancer Res Treat 2008; 112:243-54; PMID:18097747; DOI:10.1007/ s10549-007-9865-4.
47. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: Clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001; 6:419-29; PMID:12013531; DOI:10.1023/A:1014734930781.
48. Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: An effector and an effect of tumor metastasis. Curr Mol Med 2010; 10:71-81; PMID:20205680; DOI:10.2174/156652410791065381.
49. Levin VA. Basis and importance of src as a target in cancer. Cancer Treat Res 2004; 119:89-119; PMID:15164875; DOI:10.1007/1-4020-7847-1-6.
50. Tezuka K, Denhardt DT, Rodan GA, Harada S. Stimulation of mouse osteopontin promoter by v-src is mediated by a CCAAT box-binding factor. J Biol Chem 1996; 271:22713-7; PMID:8798445; DOI:10.1074/ jbc.271.37.22713.
51. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50:717-21; PMID:2297709.
52. Cailleau R, Olive M, Cruciger QV. Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization. In Vitro 1978; 14:911-5; PMID:730202; DOI:10.1007/BF02616120.
53. Xuan JW, Hota C, Chambers AF. Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J Cell Biochem 1994; 54:247-55; PMID:8175899; DOI:10.1002/ jcb.240540213.
54. Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, et al. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 2006; 23:123-33; PMID:16830223; DOI:10.1007/s10585-006-9013-2.